Journal of the Peripheral Nervous System · 2011 · 75 citations · 13 references
PharmacyNeurologyPharmacotherapyImmunopharmacotherapyNeurologic PharmacotherapyNeuropathologyMotor NeuropathyPeripheral Neuropathy ManagementDisability Assessment In NeuropathyHealth Status IndicesHealth Status TransitionMuscle Strength ProfilingPeripheral Neuropathy PharmacotherapySerious Adverse EventsSubcutaneous ImmunoglobulinSustained Improvement
Intravenous immunoglobulin (IVIG) is the first-line therapy for multifocal motor neuropathy (MMN). This open-label multi-centre study (NCT00701662) assessed the efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG) in patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients (42-66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to previous IVIG using a "smooth transition protocol". Primary efficacy endpoint was the change from baseline to week 24 in muscle strength. Disability, motor function, and health-related quality of life (HRQL) endpoints were also assessed. One patient deteriorated despite dose increase and was withdrawn. Muscle strength, disability, motor function, and health status were unchanged in all seven study completers who rated home treatment as extremely good. Four experienced 18 adverse events, of which only two were moderate. This study suggests that MMN patients with stable clinical course on regular IVIG can be switched to SCIG at the same monthly dose without deterioration and with a sustained overall improvement in HRQL.
13
Tatjana Paternostro‐Sluga, Martina Grim-Stieger, Martin Posch et al. · Journal of Rehabilitation Medicine · 2008 · 636 citations · Full text
Jean‐Marie Léger, B. Chassande, L. Musset et al. · Brain · 2001 · 279 citations · Full text
Medicine, Neurology, Pharmacotherapy +11